Getinge (OTCMKTS:GNGBY) Sets New 12-Month High – Here’s What Happened

Getinge (OTCMKTS:GNGBY)’s share price reached a new 52-week high during mid-day trading on Wednesday. The company traded as high as $26.88 and last traded at $26.76, with a volume of 2,714 shares trading hands. The stock had previously closed at $26.21.

Analysts Set New Price Targets

GNGBY has been the subject of a number of research reports. Nordea Equity Research cut shares of Getinge from a “buy” rating to a “hold” rating in a report on Monday, August 31st. UBS Group assumed coverage on Getinge in a report on Wednesday, September 2nd. They issued a “hold” rating for the company. Zacks Research downgraded shares of Getinge from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 17th. Finally, Pareto Securities downgraded Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 24th. Four research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, Getinge presently has an average rating of “Hold”.

Getinge Stock Performance

The company has a 50-day simple moving average of $25.11 and a two-hundred day simple moving average of $22.69. The company has a quick ratio of 0.74, a current ratio of 1.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.27 billion, a PE ratio of 25.42 and a beta of 0.95.

Getinge (OTCMKTS:GNGBY) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $0.32 earnings per share for the quarter. Getinge had a return on equity of 11.12% and a net margin of 7.81%. As a group, equities research analysts forecast that Getinge will post 1.38 earnings per share for the current year.

About Getinge

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.